Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03614156
Recruitment Status : Terminated (Business decision to stop the program.)
First Posted : August 3, 2018
Last Update Posted : July 19, 2019
Sponsor:
Information provided by (Responsible Party):
Naurex, Inc, an affiliate of Allergan plc

Brief Summary:
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) or 225 mg of Rapastinel compared to placebo in the prevention of relapse in participants with major depressive disorder (MDD).

Condition or disease Intervention/treatment Phase
Depressive Disorder, Major Drug: Rapastinel Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 363 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Multi-center Study of Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder
Actual Study Start Date : August 2, 2018
Actual Primary Completion Date : July 11, 2019
Actual Study Completion Date : July 11, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Rapastinel weekly
Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration)
Drug: Rapastinel
Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration) or Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)

Experimental: Rapastinel clinically driven schedule
Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
Drug: Rapastinel
Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration) or Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)

Placebo Comparator: Placebo weekly
Placebo (prefilled syringe, weekly IV administration)
Drug: Placebo
Placebo (prefilled syringe, weekly IV administration)




Primary Outcome Measures :
  1. Time to First Relapse During the 52 Weeks of the Double-Blind Treatment Period (DBTP) [ Time Frame: 52 Weeks ]
    Time in days from randomization to relapse. The primary efficacy analysis will compare the time to relapse between placebo and rapastinel treatment groups using the log-rank test.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: -

  • Completion of Study RAP-MD-30, RAP-MD-31, or RAP-MD-32
  • If female of childbearing potential, have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test

Exclusion Criteria: -

  • DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of treatment within 6 months before Visit 1
  • Lifetime history of meeting DSM-5 criteria for:
  • 1.Schizophrenia spectrum or other psychotic disorder
  • 2.Bipolar or related disorder
  • 3.Major neurocognitive disorder
  • 4.Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study
  • 5.Dissociative disorder
  • 6.Posttraumatic stress disorder
  • 7.MDD with psychotic features
  • Significant suicide risk, as judged by the Investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03614156


Locations
Show Show 52 study locations
Sponsors and Collaborators
Naurex, Inc, an affiliate of Allergan plc
Investigators
Layout table for investigator information
Study Director: Marc Debelle Allergan
Additional Information:
Layout table for additonal information
Responsible Party: Naurex, Inc, an affiliate of Allergan plc
ClinicalTrials.gov Identifier: NCT03614156    
Other Study ID Numbers: RAP-MD-33
2018-000064-28 ( EudraCT Number )
First Posted: August 3, 2018    Key Record Dates
Last Update Posted: July 19, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Naurex, Inc, an affiliate of Allergan plc:
Depression
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms